Ofatumumab - a new high-efficacy treatment for relapsing forms of multiple sclerosis

被引：0

作者：

Valis, M. ^{[1
]}

Haluskova, S. ^{[1
]}

机构：

[1] Neurol Klinika LF UK FN Hradec Kralove, Sokolska 581, Hradec Kralove 50005, Czech Republic

来源：

CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE | 2021年 / 84卷 / 05期

关键词：

multiple sclerosis; treatment; antibodies monoclonal; ofatumumab; DISEASE-ACTIVITY; NO EVIDENCE; B-CELLS; OCRELIZUMAB; THERAPIES; ANTIBODY;

D O I：

10.48095/cccsnn2021436

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

There has been tremendous progress in the treatment of MS over recent years. The concept of early treatment to achieve better outcomes in MS has clearly emerged, fully supported by long-term data. The effi cacy of anti-CD20 monoclonal antibodies in the treatment of MS has been confi rmed in clinical trials. Ofatumumab is a fully-humanized anti-CD20 monoclonal antibody approved for the treatment of adult patients with relapsing-remitting MS. Ofatumumab showed high effi cacy and a favorable safety profile in phase III clinical trials, offering the first B-cell therapy that can be subcutaneously self-administered at home.

引用

页码：436 / 440

页数：5

共 50 条

[31] Cost-Effectiveness Analysis of Ofatumumab for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada [J].

Baharnoori, Moogeh ;

Bhan, Virender ;

Clift, Fraser ;

Thomas, Kimberly ;

Mouallif, Soukaina ;

Adlard, Nicholas ;

Cooney, Philip ;

Blanchette, Francois ;

Patel, Barkha P. ;

Grima, Daniel .

PHARMACOECONOMICS-OPEN, 2022, 6 (06) :859-870

[32] Daclizumab for the treatment of relapsing-remitting multiple sclerosis [J].

Herwerth, Marina ;

Hemmer, Bernhard .

EXPERT OPINION ON BIOLOGICAL THERAPY, 2017, 17 (06) :747-753

[33] Briumvi: a breakthrough in the treatment of relapsing multiple sclerosis: a review [J].

Azhar, Ayesha ;

Taimuri, Muskan Asim ;

Shamat, Shamat Fathi ;

Ikram, Areeba ;

Ali, Sajjad ;

Ali, Tehreem ;

Khabir, Yumna .

ANNALS OF MEDICINE AND SURGERY, 2023, 85 (10) :4909-4912

[34] Performance of treatment response scoring systems among patients with multiple sclerosis treated with high-efficacy therapies [J].

Marrodan, Mariano ;

Sao Aviles, Augusto ;

Rio, Jordi ;

Cobo-Calvo, Alvaro ;

Fernandez, Victoria ;

Pappolla, Agustin ;

Castillo, Joaquin ;

Vidal-Jordana, Angela ;

Arrambide, Georgina ;

Tur, Carmen ;

Rodriguez-Acevedo, Breogan ;

Zabalza, Ana ;

Mongay-Ochoa, Neus ;

Vilaseca, Andreu ;

Rodriguez, Marta ;

Galan, Ingrid ;

Comabella, Manuel ;

Sastre-Garriga, Jaume ;

Tintore, Mar ;

Auger, Cristina ;

Rovira, Alex ;

Montalban, Xavier ;

Midaglia, Luciana .

MULTIPLE SCLEROSIS JOURNAL, 2025, :568-577

[35] An Overview of High-Efficacy Drugs for Multiple Sclerosis: Gulf Region Expert Opinion [J].

Alroughani, Raed ;

Inshasi, Jihad Said ;

Deleu, Dirk ;

Al-Hashel, Jasem ;

Shakra, Mustafa ;

Elalamy, Osama Robin ;

Shatila, Ahmed Osman ;

Al-Asmi, Abdullah ;

Al Sharoqi, Isa ;

Canibano, Beatriz Garcia ;

Boshra, Amir .

NEUROLOGY AND THERAPY, 2019, 8 (01) :13-23

[36] An Overview of High-Efficacy Drugs for Multiple Sclerosis: Gulf Region Expert Opinion [J].

Raed Alroughani ;

Jihad Said Inshasi ;

Dirk Deleu ;

Jasem Al-Hashel ;

Mustafa Shakra ;

Osama Robin Elalamy ;

Ahmed Osman Shatila ;

Abdullah Al-Asmi ;

Isa Al Sharoqi ;

Beatriz Garcia Canibano ;

Amir Boshra .

Neurology and Therapy, 2019, 8 :13-23

[37] The effect of timing of high-efficacy therapy on processing speed performance in multiple sclerosis [J].

Labiano-Fontcuberta, Andres ;

Costa-Frossard, Lucienne ;

De La Maza, Susana Sainz ;

Rodriguez-Jorge, Fernando ;

Chico-Garcia, Juan Luis ;

Monreal, Enric .

MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 64

[38] High-efficacy therapies for relapsing-remitting multiple sclerosis: implications for adherence. An expert opinion from the United Arab Emirates [J].

Inshasi, Jihad Said ;

Almadani, Abubaker ;

Al Fahad, Sarmad ;

Noori, Suzan Ibrahim ;

Alsaadi, Taoufik ;

Shakra, Mustafa ;

Shatila, Ahmed Osman ;

Zein, Tayseer Mohammed ;

Boshra, Amir .

NEURODEGENERATIVE DISEASE MANAGEMENT, 2020, 10 (04) :257-266

[39] Cladribine to Treat Relapsing Forms of Multiple Sclerosis [J].

Gavin Giovannoni .

Neurotherapeutics, 2017, 14 :874-887

[40] Cladribine to Treat Relapsing Forms of Multiple Sclerosis [J].

Giovannoni, Gavin .

NEUROTHERAPEUTICS, 2017, 14 (04) :874-887

← 1 2 3 4 5 →